(2022/01) Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses.
(2022/01) Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants.
Immune Support Scientific References
Fertility | Chronic Pain Support | General Health | Immune Support | Plant Based Nutrition | Rheumatology | Sports Nutrition | Urology | Women's Health
LATEST RESEARCH UPDATE: A recent randomized placebo-controlled trial found that palmitoylethanolamide (PEA) and luteolin supplementation improved olfactory function in those with persistent post-COVID-19 olfactory impairment. This trial compared olfactory training plus PEA-Lut (700 mg of PEA + 70 mg of Luteolin) to olfactory training plus placebo in 185 patients for 90 days. The PEA-Lut group showed significantly greater improvement in olfactory function scores (92% of patients improved versus 42% of control patients). Click here to read more.
Immune Support
Cannabidiol (CBD)
Green Tea
Melatonin
(2022/10) The role of melatonin as an adjuvant in the treatment of COVID-19: A systematic review.
(2022/02) Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection.
(2020/06) COVID-19: Melatonin as a potential adjuvant treatment.
(2020/03) Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.
(2013/10) Melatonin: its possible role in the management of viral infections-a brief review.
(2013/04) Melatonin: Buffering the Immune System.
Palmitoylethanolamide (PEA)
(2023/11) The Efficacy of Palmitoylethanolamide (Levagen+) on the Incidence and Symptoms of Upper Respiratory Tract Infection—A Double Blind, Randomised, Placebo-Controlled Trial.
(2022/06) Effects of Palmitoylethanolamide on Proinflammatory Markers in Adults Recently Diagnosed With COVID-19.
(2022/05) Palmitoylethanolamide (PEA) Inhibits SARS-CoV-2 Entry by Interacting with S Protein and ACE-2 Receptor.
(2022/04) Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial.
(2021/04) Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients.
(2017/03) Palmitoyl Ethanol Amide in Prophylaxis and Treatment of Viral Infections.
(2013/06) Palmitoylethanolamide: A Natural Body-OwnAnti-Inflammatory Agent, Effective and Safe againstInfluenza and Common Cold.
Quercetin
(2023/03) Quercetin for the treatment of COVID-19 patients: A systematic review and meta-analysis.
(2020/06) Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19).
(2012/06) Quercetin inhibits rhinovirus replication in vitro and in vivo.
Vitamin C
(2020/06) Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19).
(2019/12) The antiviral properties of vitamin C.
(2013/04) Vitamin C Is an Essential Factor on the Anti-viral Immune Responses through the Production of Interferon-α/β at the Initial Stage of Influenza A Virus (H3N2) Infection.
Vitamin D
(2024/02) Preventive Vitamin D Supplementation and Risk for COVID-19 Infection: A Systematic Review and Meta-Analysis.
(2023/08) Lack of vitamin D predicts impaired long-term immune response to COVID-19 vaccination.
(2022/06) Vitamin D and SARS-CoV2 infection, severity and mortality: A systematic review and meta-analysis.
(2022/02) COVID-19 mortality is associated with low vitamin D levels in patients with risk factors and/or advanced age.
(2022/02) Does vitamin D supplementation reduce COVID-19 severity? - a systematic review.
(2022/02) Pre-infection 25-hydroxyvitamin D3 levels and association with severity of COVID-19 illness.
(2021/06) Vitamin D supplementation and clinical outcomes in COVID‑19: a systematic review and meta‑analysis.
(2021/03) Low Serum 25-hydroxyvitamin D (Vitamin D) Level Is Associated With Susceptibility to COVID-19, Severity, and Mortality: A Systematic Review and Meta-Analysis.
(2021/03) The Impact of Vitamin D Level on COVID-19 Infection: Systematic Review and Meta-Analysis.
(2020/07) Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study.
(2020/05) Tripartite combination of potential pandemic mitigation agents: Vitamin D, Quercetin, and Estradiol manifest properties of candidate medicinal agents for mitigation of the severity of pandemic COVID-19 defined by genomics-guided tracing of SARS-CoV-2 targets in human cells.
(2020/04) Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths.
(2019/01) Vitamin D supplementation to prevent acute respiratory infections: individual participant data meta-analysis.
(2017/02) Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data.
(2016/03) A review of Vitamin D effects on common respiratory diseases: Asthma, chronic obstructive pulmonary disease, and tuberculosis.
(2015/12) Vitamin D Supplementation Modulates T Cell-Mediated Immunity in Humans: Results from a Randomized Control Trial.
Zinc
(2022/05) Zinc supplementation and COVID-19 mortality: a meta-analysis.
(2021/11) Zinc for the prevention or treatment of acute viral respiratory tract infections in adults: a rapid systematic review and meta-analysis of randomised controlled trials.
(2020/09) Analysis of the predictive factors for critical illness of COVID-19 during treatment - Relationship between serum zinc level and critical illness of COVID-19.
(2020/04) Zinc and respiratory tract infections: Perspectives for COVID 19 (Review).
(2019/07) The Role of Zinc in Antiviral Immunity.
